X-linked hypophosphatemia (XLH) is a rare hereditary disorder characterized by low levels of phosphate in the blood and bones. It is caused by defects in a gene that regulates phosphate homeostasis. Individuals with XLH experience skeletal deformities, short stature, and dental problems. Drugs used for treating XLH aim to provide additional phosphate and control abnormalities in bone and muscle mineralization.
The X-linked hypophosphatemia market is estimated to be valued at USD 1.5 Bn in 2024 and is expected to reach USD 2.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
Key players operating in the X-linked hyposphosphatemia market are Kyowa Hakko Kirin Co. Ltd., Genzyme Corporation, Nestle S.A.
Some of the key opportunities in the X-linked Hypophosphatemia Market include rising awareness about treatment options for XLH, approval and launch of novel therapeutics, and expansion in untapped emerging economies. Major players are focusing on geographical expansion strategies to capture larger market shares. For instance, in 2022, Nestle Health Science expanded its footprint in the Middle East and North Africa by launching CERNEVE® in Saudi Arabia to treat XLH.
Market Drivers
Increasing prevalence of XLH worldwide: As per research studies, the prevalence of XLH is estimated to be 1 in 20,000 live births globally. The rising incidence of this rare genetic disorder is a major factor augmenting market growth. Approvals of new treatment drugs: For example, in 2018, the approval of BIMERG025 (Burosumab) by the FDA as the first therapy to specifically treat XLH increased treatment options for patients.
Market Restraints
High cost of drugs: Phosphate replacement therapies and medications for XLH treatment involve high costs, which imposes financial burden on patients from low and middle-income nations. This acts as a major restraint.
Limited awareness: Low awareness about XLH and available treatment options, especially in underdeveloped regions, hampers timely diagnosis and management of the disease. This acts as a restraint for market growth.
Segment Analysis
This market can be segmented based on drug class and distribution channel. Based on drug class, the market can be segmented into Biphosphates, Calcitriol or Calcitriol Analogues. Among them, the Biphosphates segment holds the largest market share as they are the first line of treatment given to patients diagnosed with X-linked Hypophosphatemia. They are more effective in slowing down the disease progression as compared to other drug classes. The market can also be segmented into hospital pharmacies, retail pharmacies and online pharmacies based on the distribution channel. Hospital pharmacies dominate the segment as patients diagnosed with the disease require life-long treatment and regular monitoring by physicians. Hospital pharmacies help patients comply with complex treatment regimens and provide drugs at affordable prices.
Global Analysis
Regionally, North America dominates the X-linked Hypophosphatemia market owing to growing awareness about the disease, strong presence of key players, and well-developed healthcare infrastructure. However, Asia Pacific is expected to witness the highest growth rate over the forecast period due to increasing healthcare spending of countries in the region. Countries like China and India offer high growth potential attributed to rising incidents of X-linked Hypophosphatemia and growing focus of international players towards expanding presence in these countries. Europe holds the second largest share in the global market due to supportive government initiatives and funds provided for research on rare diseases.
Get this Report in Japanese Language: X連鎖性低リン血症市場
Get this Report in Korean Language: X연관 저인산혈증 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
